AtaiBeckley Inc.

AtaiBeckley Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of mental health treatments. Its pipeline includes several drug candidates targeting conditions such as treatment-resistant depression (TRD), alcohol use disorder, cognitive impairment associated with schizophrenia, major depressive disorder, social anxiety disorder, and various neurological disorders. Notable programs include BPL-003, an intranasal formulation of mebufotenin in Phase 2a and 2b trials for TRD and alcohol use disorder; RL-007, a pro-cognitive neuromodulator in Phase 2b for schizophrenia; and ELE-101, a serotonergic psychedelic for major depressive disorder. The company also develops VLS-01, an oral transmucosal film of DMT for TRD, and EMP-01, an oral MDMA derivative for social anxiety disorder. Additionally, it works on non-hallucinogenic 5-HT2A receptor agonists (EGX-A and EGX-B) and COMP360 for psilocybin therapy.

AtaiBeckley Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol ATAI. Its shares are traded in US Dollars (USD), reflecting its primary listing in the United States. The company is headquartered in New York, New York, and was founded in 2018. It was formerly known as Atai Beckley N.V. before rebranding to AtaiBeckley Inc. in December 2025.

AtaiBeckley Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and cognitive impairment. Its research and development efforts are centered on psychedelic and non-hallucinogenic compounds, positioning it within the emerging field of psychedelic medicine and neuropsychiatric treatments.

AtaiBeckley Inc. is headquartered in New York, New York, and conducts its research, development, and commercialization activities primarily in the United States, Germany, and Canada. The company's clinical trials and operations span these regions, allowing it to access diverse patient populations and regulatory environments. Its pipeline targets mental health conditions prevalent in these markets, such as treatment-resistant depression and alcohol use disorder.

AtaiBeckley Inc. is a clinical-stage biopharmaceutical company that generates no approved product revenue yet; its business model focuses on advancing a pipeline of mental health treatments through clinical development and eventual commercialization. Key portfolio highlights include BPL-003 (intranasal mebufotenin) for treatment-resistant depression and alcohol use disorder, RL-007 for cognitive impairment in schizophrenia, ELE-101 for major depressive disorder, VLS-01 (oral DMT film) for TRD, EMP-01 (oral MDMA derivative) for social anxiety disorder, and non-hallucinogenic 5-HT2A agonists EGX-A and EGX-B. It also develops COMP360 for psilocybin therapy and GRX-917 for anxiety, depression, and neurological disorders. The company's strategy involves targeting large unmet needs in mental health through both psychedelic and non-psychedelic approaches.